BioAge Labs, Inc.
- Last sale
- Nov 12, 2026 · -3.41%
- Market cap
- $260.13M
- 45.96M shares
- Filings
- 158
Q3 2026
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−46.7% FY25 yoy
- $260.13M
- —
- 30.3×
- 0.8×
- -39.60%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $8,995,000 | reported | |
| FY 2024 | 2024-12-31 | $0 | reported |
Pharmaceutical preparations
BioAge Labs, Inc. is the 174th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
JANXJanux Therapeutics, Inc.$10.0M5.6%1,136.3%$1.0BZBIOZenas BioPharma, Inc.$10.0M100.0%3,777.4%$1.9BPGENPrecigen, Inc.$9.7M146.7%2,588.2%$1.7BPRTAProthena Corp Public Ltd Co$9.7M92.8%2,520.6%$422.1MISCOInternational Stem Cell CORP$9.1M0.2%4.6%$2.6M
BIOABioAge Labs, Inc. (this company)$9.0M—896.1%$260.1M
ROIVRoivant Sciences Ltd.$8.3M71.6%3,629.2%$29.0BCOYACoya Therapeutics, Inc.$7.9M123.6%267.1%$75.8MACRSAclaris Therapeutics, Inc.$7.8M58.2%829.6%$635.2MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
BioAge Labs, Inc. · CIK 1709941 · Engraved from SEC EDGAR